Uncategorized Archives - Page 4 of 142

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to…

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

TuesdayAug 05, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl” Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug's safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable…

TuesdayJul 29, 2025 1:45 pm

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis. The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial. IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging. A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones. Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility. Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of…

MondayJul 28, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need. Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors. Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025. Clene is preparing to initiate a confirmatory Phase 3 ALS trial…

ThursdayJul 24, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results

Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially lowering quality of life. Soligenix has taken on this challenge with SGX942, a treatment aimed at reducing tissue inflammation, promoting healing and supporting immune response. The company is in the process of analyzing combined phase 2 and 3 datasets to design a second phase 3 study. Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed…

FridayJul 18, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and…

FridayJul 11, 2025 10:00 am

Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases

Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities. The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life. For example, malaria claims at least 600,000 lives globally each year, with most of these fatalities happening in low-income countries. Sub-Saharan Africa accounts for approximately 95% of this annual toll. The new test is intended to facilitate rapid diagnostics outside a lab in resource-constrained settings. In low-income countries, healthcare workers often administer treatment without…

ThursdayJul 10, 2025 9:00 am

New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer

A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%. Glioblastoma, or GBM, is the most common type of brain cancer, and fatalities from this cancer are high. On average, individuals diagnosed with this type of cancer survive for 14 months only. While this link between TBIs and GBM…